Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19

Qiang Hu

Status

Completed

Conditions

Lymphopenia

Covid19

Treatments

Drug: nicotinamide

Study type

Interventional

Funder types

Other

Identifiers

NCT04910230

N2020-12

Details and patient eligibility

About

The mechanism of peripheral blood lymphocyte decline in COVID-19 patients is not yet clear. However, one theory demonstrated that in the whole progression of COVID-19, the extensive activation of poly-ADP-ribose polymerase (PARP) may reduce the cellular NAD+ and dampen the adaptive immune system. So investigators presume that replenishing the NAD+ using nicotinamide as the precursor may improve the lymphocyte counts and boost the adaptive immune system. As a result, the study using nicotinamide as a kind of supportive therapy provide further evidence of their efficiency and safety in treating lymphopenia in patients with COVID-19.

Enrollment

24 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

the patients diagnosed as the common or severe cases of COVID-19
aged 18-85
the absolute lymphocyte counts below the normal value (<1.1-3.2×109/L)

Exclusion criteria

the patients who are diagnosed as critically ill cases or participating in other clinical trials
women who are pregnant or lactating
ALT/AST > 5 times upper limit of normal (ULN), neutrophils counts < 0.5×109/L, platelets counts< 50×109/L
patients diagnosed with rheumatoid immune-related diseases
patients who take long-term oral anti-rejection drugs or immunomodulatory drugs
hypersensitive reaction to nicotinamide or any auxiliary materials
patients with active tuberculosis or combined with bacterial and fungal infections
patients undergoing organ transplant
patients with mental disorders.